Apabetalone 10 mg | 99.00%
TargetMol
RVX-208, an effective BET bromodomain inhibitor, has been investigated for the treatment of diabetes, atherosclerosis, and coronary artery disease.
More Information Supplier PageApabetalone
Search Results
ZMC1 5 mg | 97.48%
TargetMol
NSC319726, a mutant p53R175 reactivator, suppresses growth of fibroblasts that expresses the p53R175 mutation (IC50 = 8 nM).
More Information Supplier PageZMC1
ZMC1 50 mg | 97.48%
TargetMol
NSC319726, a mutant p53R175 reactivator, suppresses growth of fibroblasts that expresses the p53R175 mutation (IC50 = 8 nM).
More Information Supplier PageZMC1
ZMC1 10 mg | 97.48%
TargetMol
NSC319726, a mutant p53R175 reactivator, suppresses growth of fibroblasts that expresses the p53R175 mutation (IC50 = 8 nM).
More Information Supplier PageZMC1
ML141 5 mg | 99.77%
TargetMol
ML141 is an effective, specific and reversible non-competitive inhibitor of Rho family GTPase cdc42 (IC50: 200 nM).
More Information Supplier PageML141
NU 7026 25 mg | 100.00%
TargetMol
NU7026 is an effective DNA-PK inhibitor (IC50: 0.23 μM, in cell-free assays), 60-fold selective for DNA-PK than PI3K and no inhibition against both ATM and ATR.
More Information Supplier PageNU 7026
NU 7026 10 mg | 100.00%
TargetMol
NU7026 is an effective DNA-PK inhibitor (IC50: 0.23 μM, in cell-free assays), 60-fold selective for DNA-PK than PI3K and no inhibition against both ATM and ATR.
More Information Supplier PageNU 7026
PNU-282987 50 mg | 99.00%
TargetMol
PNU-282987 is a selective α7 nicotinic acetylcholine receptor(α7 nAChR) agonist with Ki of 26 nM; no affinity for α1β1γδ and α3β4 nAChRs (IC50 ≥ 60 μM).
More Information Supplier PagePNU-282987
SKLB1002 5 mg | Purity Not Available
TargetMol
SKLB1002 is a potent and ATP-competitive VEGFR2 inhibitor with IC50 of 32 nM.
More Information Supplier PageSKLB1002
SKLB1002 25 mg | Purity Not Available
TargetMol
SKLB1002 is a potent and ATP-competitive VEGFR2 inhibitor with IC50 of 32 nM.
More Information Supplier PageSKLB1002